

## Maytanprine and Maytanbutine, New Antileukaemic Ansa Macrolides from *Maytenus buchananii*<sup>1</sup>

By S. MORRIS KUPCHAN, YASUO KOMODA, GARETH J. THOMAS, and H. P. J. HINTZ

(Department of Chemistry, University of Virginia, Charlottesville, Virginia 22901)

**Summary** The structures of maytanprine (2) and maytanbutine (3), new antileukaemic ansa macrolides from *Maytenus buchananii* (Loes.) R. Wilczek, have been determined.

$C_{35}H_{48}ClN_3O_{10}$ , m.p. 169–170°,  $[\alpha]_D^{30} - 125^\circ$  (c 0.0559,  $CHCl_3$ ), and maytanbutine (3) (0.00009%),  $C_{38}H_{50}ClN_3O_{10}$ , m.p. 170–171°,  $[\alpha]_D^{30} - 122^\circ$  (c 0.0492,  $CHCl_3$ ). The i.r. and u.v. spectra of (2) and (3) were almost identical to those of (1).

RECENTLY, we reported the isolation and structural elucidation of maytansine (1), a novel antileukaemic ansa macrolide tumour inhibitor from *Maytenus ovatus*.<sup>2</sup> We now describe two new and potent antileukaemic ansa macrolides isolated from *Maytenus buchananii* (Loes.) R. Wilczek, maytanprine (2) and maytanbutine (3). The new principles showed antileukaemic activity against P-388 lymphocytic leukaemia over a 50–100-fold dosage range at the  $\mu g\ kg^{-1}$  level.<sup>3</sup>

The alcoholic extract of stems collected in Kenya in 1970 was fractionated by the procedure summarized earlier,<sup>2</sup> to yield a highly enriched concentrate. Preparative t.l.c. on silica gel afforded maytansine (1) (0.00015%) and two bands of higher  $R_F$ . Purification by high pressure liquid chromatography yielded maytanprine (2) (0.00012%),


The principal peaks in the mass spectra of (1)–(3) are listed in the Table; the compositions of the fragment ions were determined by high resolution m.s. The m.s. characteristics indicated that (2) and (3) have ansa macrolide structures similar to (1) except for differences in the R-groups of the ester side chains.

The relationships among the three compounds were confirmed by comparisons of their n.m.r. spectra. Thus, the n.m.r. spectra of (2) and (3) differed from that of (1) solely in the signals corresponding to the terminal R-CO groups. The n.m.r. signals for the propionyl group of (2) [ $\tau$  8.82 (3H, t, J 7), 7.63 (1H, m), 7.59 (1H, m)] indicated the non-equivalence of the methylene protons, and this was confirmed by spin-decoupling studies.<sup>4,5</sup> The n.m.r. signals for the isobutyryl group of (3) [ $\tau$  8.88 (3H, d, J 7), 8.81 (3H, d, J 7), 7.20 (1H, m)] suggested the non-equiva-

TABLE. Mass spectral characteristics<sup>a</sup>

	$M^+ - (a)$	$M^+ - (a + b)$	485 - (Me)	485 - (Cl)	[(b) - (OH)] <sup>+</sup>	[(b) - (COOH)] <sup>+</sup>	$C_3H_8N^+$	$C_2H_6N^+$
(1)	630	485	470	450	128	100	58	44
(2)	644	485	470	450	142	114	58	44
(3)	658	485	470	450	156	128	58	44

<sup>a</sup> (a) =  $H_2O + HNCO$ ; (b) =  $R \cdot CO \cdot NMe \cdot CHMe \cdot COOH$



- (1) R = Me  
 (2) R =  $CH_2Me$   
 (3) R =  $CHMe_2$

lence of the two methyl groups, and this also was supported by the results of spin decoupling and solvent shift studies. The signals for the C-2' N- $CH_3$  of (3) [ $\tau$  7.13 (3/4H, s), 7.08 (2-1/4H, s)] indicated that the rate of rotation about the carbonyl to nitrogen bond was reduced by the steric interaction of the isopropyl group and the aromatic ring<sup>4,5</sup>

Studies of other active principles of *M. buchananii* are in progress.

We thank Dr. Robert E. Perdue, jun., for supplying the plant material and the National Cancer Institute (Chemotherapy) for financial support.

(Received 31st July 1972; Com. 1328.)

<sup>1</sup> For previous paper in the series 'Tumor Inhibitors' see: S. M. Kupchan, W. A. Court, R. G. Dailey, jun., C. J. Gilmore, and R. F. Bryan, *J. Amer. Chem. Soc.*, in the press.

<sup>2</sup> S. M. Kupchan, Y. Komoda, W. A. Court, G. J. Thomas, R. M. Smith, A. Karim, C. J. Gilmore, R. C. Haltiwanger, and R. F. Bryan, *J. Amer. Chem. Soc.*, 1972, **95**, 1354.

<sup>3</sup> Anti-leukaemic activity was assayed under the auspices of the National Cancer Institute, by the procedures described in *Cancer Chemotherapy Reports*, 1962, **25**, 1.

<sup>4</sup> T. H. Siddall and W. E. Stewart, in 'Progress in N.M.R. Spectroscopy,' ed. J. W. Emsley, J. Feeney, and L. H. Sutcliffe, Pergamon Press, New York, 1969. Volume 5, p. 33.

<sup>5</sup> L. M. Jackman and S. Sternhell, 'Applications of Nuclear Magnetic Resonance Spectroscopy in Organic Chemistry,' 2nd edn., Pergamon Press, New York, 1969, p. 368.